non-cardiac uptake of technetium-99m pyrophosphate in transthyretin cardiac amyloidosis

Technetium-based bone scintigraphy is rapidly becoming the most common non-invasive imaging tool in the diagnosis of transthyretin cardiac amyloidosis (attr). skeletal muscle uptake has been described with technetium-99m-3,3-diphosphono-1,2-propanodicarboxylic acid (tcdpd), and account for masking of bony uptake. we sought to investigate skeletal muscle uptake of technetium-99m-pyrophosphate (tcpyp) in patients with attr. this was a retrospective analysis of 57 patients diagnosed with attr who underwent tcpyp scintigraphy. cardiac uptake was assessed on whole-body planar imaging using a semiquantitative scale (grades 0 to 3) and on single-photon emission computed tomography (spect) with ct attenuation correction using total myocardial counts per voxel after a 3-hour incubation. skeletal muscle (psoas and biceps), vertebral body, lv myocardium, and blood pool mean counts were calculated. in the cohort (age 78 ± 9 years, 77% male, and 30% hereditary attr), there was no visualized tracer uptake in skeletal muscle or soft tissue on qualitative spect assessment. total and blood pool-corrected uptake in the muscle groups were significantly less than myocardium and bone (p < 0.001). blood pool-corrected muscle uptake was not associated with semiquantitative grade 3 vs 2 uptake (psoas p = 0.66, biceps p = 0.13) or presence of hereditary attr (psoas p = 0.43, biceps p = 0.69). as bony uptake decreased, there was no corresponding increase in skeletal muscle uptake. in patients with attr cardiac amyloidosis, skeletal muscle uptake of tcpyp is minimal when assessed by qualitative and quantitative metrics, and is not significantly different in patients with grade 2 vs 3 semiquantitative uptake. the properties of this tracer be different than tcdpd with respect to non-cardiac uptake.